Sarah A. Delashmit was a camp counselor when she struck up a close friendship with Erin Johnson, a woman with cerebral palsy ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD).

This award honors an emerging leader shaping the future of neuromuscular research will be presented at the 2026 MDA Clinical ...

Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 ...

MDA Ambassadors: Justin living with limb-girdle muscular dystrophy (LGMD) 2B, Caroline living with collagen VI muscular dystrophy, A.J. living with inclusion body myositis (IBM) and ...

Chugai Pharma introduces “Elevidys” as Japan’s first regenerative medical product for Duchenne muscular dystrophy: Tokyo Monday, February 23, 2026, 11:00 Hrs [IST] Chugai Ph ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

Dyne’s posters and presentations at the 2026 MDA Clinical & Scientific Conference will include: New analyses of the results of the DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also ...

New York, Jan. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day on February 28, the Muscular Dystrophy Association (MDA) is sharing powerful community stories throughout the month that ...

Del-desiran reduced DMPK mRNA levels, but led to two serious adverse events ...

Aarhus, Denmark, 12 February 2026 - NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data ...